SKYE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Skye Bioscience Inc (SKYE) is not a strong buy at this moment for a beginner investor with a long-term strategy. The stock lacks significant positive catalysts, has no recent trading signals, and its financial performance shows improvement but remains negative overall. Given the absence of strong growth indicators and limited trading sentiment, holding off on this investment would be prudent.
The MACD histogram is positive at 0.0179, indicating a slight bullish momentum, but it is contracting. RSI is neutral at 57.54, and moving averages are converging, showing no clear trend. Support and resistance levels suggest a narrow trading range with a pivot at 0.728, resistance at 0.808, and support at 0.648.
No recent news or significant positive events. Financials show improvement in net income and EPS, but they are still negative.
No recent congress trading data, no hedge fund or insider activity, and no significant trading trends. The stock's financials remain weak with no revenue and negative net income.
In Q4 2025, the company reported no revenue growth (0% YoY) and a net income of -$14,441,963, which improved by 48.18% YoY. EPS increased to -0.36, up 50% YoY. Gross margin remains at 0%.
No recent analyst ratings or price target changes available.
